Safety, PK and Antiviral Activity of PGT121 Monoclonal Antibody in HIV-uninfected and HIV-infected Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

July 8, 2019

Study Completion Date

July 8, 2019

Conditions
HIV Infection
Interventions
BIOLOGICAL

PGT121 3mg/kg IV

3mg/kg administered by IV Infusion

BIOLOGICAL

PGT121 10mg/kg IV

10mg/kg administered by IV infusion

BIOLOGICAL

PGT121 30mg/kg IV

30mg/kg administered by IV infusion

BIOLOGICAL

PGT121 3mg/kg SC

"3mg/kg administered by SC injection~Placebo: None"

BIOLOGICAL

Placebo (0.9% Sodium Chloride Injection USP (Saline))

Trial Locations (1)

02215

Beth Israel Deaconess Medical Center, Boston

All Listed Sponsors
collaborator

Beth Israel Deaconess Medical Center, Boston MA

UNKNOWN

collaborator

Ragon Institute of MGH, MIT and Harvard, Boston MA

UNKNOWN

collaborator

University of Texas Health, Houston AIDS Research Team (HART), Houston TX

UNKNOWN

collaborator

Mills Clinical Research, Los Angeles CA

UNKNOWN

collaborator

Orlando Immunology Clinic, Orlando FL

UNKNOWN

lead

International AIDS Vaccine Initiative

NETWORK

NCT02960581 - Safety, PK and Antiviral Activity of PGT121 Monoclonal Antibody in HIV-uninfected and HIV-infected Adults | Biotech Hunter | Biotech Hunter